APP/PS1 Double Transgenic Mouse Model

APP/PS1 Double Transgenic Mouse Model

Overview

The APP/PS1 double transgenic mouse model, also known as APPswe/PS1ΔE9 or simply APP/PS1, is one of the most widely used animal models for studying Alzheimer's disease amyloid pathology. This model co-exembles mutant forms of the amyloid precursor protein (APP) with mutant presenilin 1 (PS1), leading to accelerated amyloid-beta (Aβ) deposition in the brain [@jankord2009].

Genetic Background

The APP/PS1 double transgenic model exists in two main variants distinguished by their PS1 mutation: PS1ΔE9 (exon 9 deletion) and PS1 M146L (point mutation). Both variants are widely used in AD research with similar amyloid phenotypes but distinct genetic mechanisms.

APPswe Mutation

The APPswe mutation (Swedish) involves a double mutation (K670N/M671L) at the APP cleavage site:

• Location: Amino acids 670-671 of APP770 isoform
• Effect: Increases β-secretase cleavage, dramatically elevating Aβ production
• Origin: First identified in Swedish familial AD cases
• Aβ elevation: 3-5 fold increase in total Aβ production [@moechars1999]

PS1ΔE9 Mutation

The PS1ΔE9 mutation is a deletion of exon 9 in the presenilin 1 gene:

• Effect: Creates a constitutively active γ-secretase with altered cleavage specificity
• Result: Shifts Aβ production toward the more aggregation-prone Aβ42 species
• Inheritance: Autosomal dominant, early-onset familial AD [@borchelt1996]

PS1 M146L Mutation (APP/PS1-M146L Variant)

...

APP/PS1 Double Transgenic Mouse Model

Overview

The APP/PS1 double transgenic mouse model, also known as APPswe/PS1ΔE9 or simply APP/PS1, is one of the most widely used animal models for studying Alzheimer's disease amyloid pathology. This model co-exembles mutant forms of the amyloid precursor protein (APP) with mutant presenilin 1 (PS1), leading to accelerated amyloid-beta (Aβ) deposition in the brain [@jankord2009].

Genetic Background

The APP/PS1 double transgenic model exists in two main variants distinguished by their PS1 mutation: PS1ΔE9 (exon 9 deletion) and PS1 M146L (point mutation). Both variants are widely used in AD research with similar amyloid phenotypes but distinct genetic mechanisms.

APPswe Mutation

The APPswe mutation (Swedish) involves a double mutation (K670N/M671L) at the APP cleavage site:

• Location: Amino acids 670-671 of APP770 isoform
• Effect: Increases β-secretase cleavage, dramatically elevating Aβ production
• Origin: First identified in Swedish familial AD cases
• Aβ elevation: 3-5 fold increase in total Aβ production [@moechars1999]

PS1ΔE9 Mutation

The PS1ΔE9 mutation is a deletion of exon 9 in the presenilin 1 gene:

• Effect: Creates a constitutively active γ-secretase with altered cleavage specificity
• Result: Shifts Aβ production toward the more aggregation-prone Aβ42 species
• Inheritance: Autosomal dominant, early-onset familial AD [@borchelt1996]

PS1 M146L Mutation (APP/PS1-M146L Variant)

The PS1 M146L mutation is a point mutation replacing methionine with leucine at position 146:

• Location: transmembrane domain II of PS1 ( residue M146)
• Effect: Subtle alteration of γ-secretase substrate specificity
• Aβ shift: Increases Aβ42/Aβ40 ratio (~2-3 fold)
• Origin: One of the most common FAD PSEN1 mutations, first identified in families with early-onset AD
• Pathology onset: Similar to PS1ΔE9, plaques detectable by 5-8 months

The APP/PS1-M146L model uses the same APPswe mutation but pairs it with the M146L point mutation instead of the ΔE9 deletion. Both models produce robust amyloid pathology, but the M146L variant represents a more subtle genetic alteration while still accelerating Aβ42 production.

Comparison: PS1ΔE9 vs PS1 M146L

| Feature | APP/PS1ΔE9 | APP/PS1-M146L |
|---------|------------|---------------|
| PS1 mutation | Exon 9 deletion | M146L point mutation |
| Genetic mechanism | Large genomic deletion | Single amino acid substitution |
| Aβ42/Aβ40 increase | ~5-10 fold | ~2-3 fold |
| Plaque onset | 6 months | 5-8 months |
| Phenotype severity | Moderate-severe | Moderate |
| Research use | Most common | Less common |

Breeding Strategy

The model uses:

• Co-integration: Both transgenes integrated on separate chromosomes
• Promoter: Mouse prion protein (PrP) promoter drives neuronal expression
• Background: C57BL/6J x C3H hybrid background
• Expression: High-level expression in neurons throughout the brain [@radde2006]

Pathological Features

Amyloid Plaque Formation

APP/PS1 mice develop robust amyloid pathology:

• Onset: Plaques detectable by 6 months of age
• Distribution: Cortex and hippocampus first, spreading to striatum later
• Plaque types: Both diffuse and neuritic (cored) plaques
• Density: High plaque burden by 9-12 months [@garciaalloza2006]

Amyloid-Beta Species

The model produces multiple Aβ species:

• Aβ40: Present but less abundant
• Aβ42: Major species, highly elevated
• Oligomers: Soluble toxic oligomers detectable
• N3py: Pyroglutamate-modified Aβ (in older mice) [@wirths2009]

Additional Pathology

Beyond amyloid, these mice show:

• Gliosis: Activated microglia surrounding plaques
• Synaptic loss: Reduced synaptic markers in plaque-rich regions
• Neuroinflammation: Elevated cytokines and complement proteins
• Behavioral deficits: Learning and memory impairments [@heneka2013]

Phenotypic Characteristics

Cognitive Deficits

APP/PS1 mice exhibit:

• Spatial memory deficits: Impaired performance in Morris water maze
• Learning impairment: Deficits in contextual fear conditioning
• Working memory: Problems in radial arm maze
• Onset: Behavioral deficits appear by 7-9 months [@morgan2000]

Physiological Changes

• LTP impairment: Reduced hippocampal long-term potentiation
• Synaptic plasticity: Altered NMDA receptor function
• Network dysfunction: Hyperexcitability in cortical circuits
• Neurogenesis: Reduced adult hippocampal neurogenesis [@shen2002]

Peripheral Pathology

The model also shows:

• Cerebral amyloid angiopathy: Aβ deposition in blood vessels
• Body weight: Slightly reduced compared to wild-type
• Lifespan: Normal or slightly reduced [@van2006]

Research Applications

Therapeutic Testing

APP/PS1 mice are used to test:

• Anti-amyloid therapies: Immunotherapies, secretase inhibitors
• Aggregation inhibitors: Compounds targeting Aβ oligomerization
• Anti-inflammatory agents: Microglial modulators
• Gene therapy approaches: Various intervention strategies [@schenk1999]

Mechanism Studies

The model enables investigation of:

• Amyloid toxicity mechanisms: How Aβ causes neuronal dysfunction
• Inflammation role: Microglia-neuron interactions
• Spread of pathology: Braak-like progression of plaques
• Biomarker development: CSF and blood Aβ measurements [@cai2012]

Advantages and Limitations

Advantages

• Robust amyloid pathology: Consistent, abundant plaque formation
• Rapid onset: Pathology develops faster than single transgenics
• Well-characterized: Extensive baseline data available
• Reproducible: Consistent phenotype across laboratories [@oddo2006]

Limitations

• No tau pathology: Lacks neurofibrillary tangles
• No neuronal loss: Significant neuronal death not observed
• Non-physiological expression: Prion promoter driving expression
• Mouse APP differences: Species-specific APP processing [@kelley2019]

Comparison to Other Models

| Model | APP Mutation | PS Mutation | Plaque Onset | Key Features |
|-------|-------------|-------------|--------------|--------------|--------------|
| APP/PS1ΔE9 | Swedish | ΔE9 | 6 months | High Aβ42, robust plaques |
| APP/PS1-M146L | Swedish | M146L | 5-8 months | High Aβ42, moderate plaques |
| 3xTg | Swedish + London | ΔE9 | 6-12 months | Both amyloid and tau |
| 5xFAD | 3 APP + 2 PS1 | M146L + L286V | 2 months | Very rapid, severe |
| Tg2576 | Swedish | None | 9-12 months | Slower, pure amyloid |

Biomarker Correlations in APP/PS1

CSF Biomarker Trajectories

APP/PS1 mice show characteristic changes in cerebrospinal fluid biomarkers that mirror patterns observed in human AD[@liu2023]:

• Aβ42: Decreases in brain tissue while increasing in CSF, reflecting plaque sequestration
• Total tau: Progressive elevation in both brain and CSF correlating with neurodegeneration
• Phosphorylated tau: Increases in CSF, reflecting tau pathology development
• Neurofilament light chain (NfL): Rising levels indicate axonal damage and disease progression

The temporal dynamics of these biomarkers provide insights into disease staging and therapeutic response monitoring. Studies using longitudinal CSF sampling demonstrate that biomarker changes precede behavioral deficits, enabling early intervention studies[@liu2023].

Blood-Based Biomarkers

Recent advances have enabled detection of AD biomarkers in mouse plasma[@mastrogiovanni2022]:

• Plasma Aβ40/Aβ42: Elevated ratios correlate with brain plaque burden
• Plasma tau: p-tau181 shows promise as a progression marker
• NfL: Peripheral indicator of neuronal injury
• glial fibrillary acidic protein (GFAP): Astrocyte activation marker

These blood-based biomarkers offer minimally invasive approaches for monitoring disease progression and therapeutic efficacy in preclinical studies.

Metabolic Dysfunction in APP/PS1

Brain Metabolism alterations

APP/PS1 mice exhibit progressive brain metabolic deficits[@zhang2023]:

• Glucose hypometabolism: Early reduction in hippocampal and cortical glucose utilization
• Mitochondrial dysfunction: Impaired complex IV activity and ATP production
• Lactate accumulation: Shift toward anaerobic metabolism in advanced stages
• Insulin resistance: Impaired brain insulin signaling contributes to cognitive decline

FDG-PET imaging in APP/PS1 mice reveals regional patterns of hypometabolism that correlate with amyloid deposition and cognitive impairment. These metabolic changes provide targets for metabolic interventions.

Systemic Metabolism

Beyond CNS changes, APP/PS1 mice show systemic metabolic alterations:

• peripheral insulin resistance: Contributing to overall metabolic dysfunction
• Dyslipidemia: Altered lipid profiles similar to human AD
• Weight changes: Age-related weight loss in advanced stages
• Glucose intolerance: Pre-diabetic metabolic state in some colonies

Understanding these systemic metabolic changes informs comprehensive therapeutic approaches targeting whole-body physiology.

Synaptic Circuit Dysfunction

Network-Level Changes

APP/PS1 mice exhibit profound synaptic circuit alterations beyond individual synapse loss[@forrest2024]:

• Hippocampal circuit dysfunction: Impaired CA3-CA1 synaptic transmission and place cell instability
• Cortical network hyperconnectivity: Early increased connectivity followed by progressive disconnection
• Gamma oscillation abnormalities: Disrupted gamma rhythms impair information processing
• Sharp wave-ripple disruptions: Altered memory consolidation dynamics

These network-level changes explain the cognitive deficits that exceed what would be predicted from synaptic marker loss alone. Restoring network function represents a therapeutic target distinct from amyloid clearance.

Circuit-Specific Vulnerabilities

Specific neural circuits show differential vulnerability in APP/PS1 mice:

• Entorhinal cortex: Early hyperactivity and later hypoactivity
• Subiculum: Progressive dysfunction affecting hippocampal output
• Pyramidal cells: Layer-specific vulnerability within cortical regions
• Inhibitory interneurons: Selective loss of specific interneuron subtypes

Understanding circuit-specific vulnerabilities enables targeted interventions that address the earliest functional deficits.

Therapeutic Translation Challenges

translational Gaps

Despite robust efficacy in APP/PS1 models, many therapeutic approaches fail in human trials[@deutsch2024]:

• Species differences in Aβ sequences: Mouse Aβ differs from human Aβ in key residues
• Immunotherapy limitations: Anti-Aβ antibodies show limited cognitive benefit despite plaque reduction
• Age at intervention: Mouse studies often start before significant pathology, unlike human trials
• Trial duration: Chronic progressive diseases require longer intervention periods than typical preclinical studies

These translation challenges highlight the need for improved model systems and better clinical trial design.

Combination Therapy Rationale

Given the multifactorial nature of AD, combination approaches show promise:

• Amyloid removal plus tau targeting: Addressing multiple pathological proteins
• Anti-inflammatory plus anti-amyloid: Targeting neuroinflammation alongside Aβ
• Metabolic enhancement plus amyloid clearance: Supporting neuronal energy needs
• Synaptic protection plus disease modification: Preserving function while treating cause

APP/PS1 models provide a platform for testing combination approaches that may improve translation to human trials.

Advanced Imaging Applications

Multiphoton Microscopy

In vivo two-photon imaging enables visualization of dynamic processes in APP/PS1 mice[@rosen2023]:

• Plaque formation dynamics: Real-time monitoring of plaque growth and stability
• Microglial surveillance: Visualizing microglial responses to amyloid deposits
• Vascular changes: Tracking blood-brain barrier alterations and cerebral blood flow
• Dendritic spine remodeling: Longitudinal analysis of synaptic structural changes

These imaging approaches reveal processes invisible in endpoint histology and enable time-course studies within individual animals.

PET Molecular Imaging

Advanced PET tracers allow molecular characterization in living mice:

• Amyloid PET: [11C]PiB, [18F]florbetapir for plaque imaging
• Tau PET: Tracking tau pathology development in models with tau
• Metabolic PET: FDG-PET for functional assessment
• Inflamation PET: TSPO imaging for microglial activation

Correlating PET signals with histopathology validates imaging biomarkers for preclinical therapeutic screening.

See Also

• [APP](/proteins/app)
• [Presenilin-1](/proteins/psen1-protein)
• [3xTg-AD Mouse Model](/mechanisms/3xtg-ad-mouse)
• [5xFAD Mouse Model](/mechanisms/5xfad-mouse)
• [APP Processing](/mechanisms/app-processing)
• [Amyloid-Beta](/proteins/amyloid-beta)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)